US Stock MarketDetailed Quotes

NRIX Nurix Therapeutics

Watchlist
  • 19.510
  • +0.610+3.23%
Close Jan 8 16:00 ET
  • 19.510
  • 0.0000.00%
Post 16:20 ET
1.38BMarket Cap-6.73P/E (TTM)

Nurix Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Nurix Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 6 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 14.740M--
--2024/Q4-- / 12.877M--
--2024/Q312.588M / 12.253M--
--2024/Q212.092M / 21.784M--
--2024/Q116.585M / 17.085M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 14.740M--
--2024/Q4-- / 12.877M--
--2024/Q312.588M / 12.253M--
--2024/Q212.092M / 21.784M--
--2024/Q116.585M / 17.085M--

Unlock Free Earnings Estimates

Nurix Therapeutics Earnings Reports

  • Nurix Therapeutics | 10-Q: Q3 2024 Earnings Report

    Oct 11, 2024 16:10 ET

  • Nurix Therapeutics | 10-Q: Q2 2024 Earnings Report

    Jul 11, 2024 16:09 ET

  • Nurix Therapeutics | 10-Q: Q1 2024 Earnings Report

    Apr 10, 2024 07:07 ET

  • Nurix Therapeutics | 10-K: FY2023 Annual Report

    Feb 15, 2024 22:20 ET

    • Read more

    Trending US Stocks
    Best Growth Stocks Best Growth Stocks

    Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

    Symbol Mini Chart % Chg
    Collegium Pharmaceutical
    COLL
    +14.41%
    eBay
    EBAY
    +9.86%
    Halozyme Therapeutics
    HALO
    +5.02%
    SilverCrest Metals
    SILV
    +4.63%
    Workday
    WDAY
    +2.01%

    Unlock the Full List

    Analysis

    Analyst Rating

    Updated: Jan 8, 2025

    Strong Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data